Nature study backs PeriFlow’s capillary-selective heart attack drug

A Nature study says PeriFlow Therapeutics’ CLN-2501 can rapidly reopen constricted capillaries after acute myocardial infarction, a mechanism that could improve survival and reduce heart failure after a heart attack. The findings target capillary no-reflow, a major gap in care even after stents restore the blocked artery.

Why it matters: - Capillary no-reflow remains an unsolved problem after many heart attacks, even when doctors successfully reopen the blocked coronary artery. - Patients with capillary no-reflow can end up with larger areas of heart muscle damage, more heart failure and worse survival. - No approved therapy specifically targets capillary no-reflow.

What happened: - A study published in Nature reports a new therapeutic strategy for acute myocardial infarction centered on capillary no-reflow. - PeriFlow Therapeutics’ lead candidate, CLN-2501, is described as the first capillary-selective vasodilator and the first drug candidate developed specifically to treat capillary no-reflow. - The research links back to work by Dr. András Málnási-Csizmadia and his biochemistry team in Budapest and Boston.

The details: - The team identified a smooth-muscle-myosin inhibitor that binds directly to myosin in capillaries and relaxes the pathological hypercontraction. - In preclinical models, CLN-2501 reopened capillaries and restored blood flow within seconds. - The treatment substantially reduced tissue injury and improved survival. - CLN-2501 preserved normal vascular autoregulation and systemic hemodynamics. - The therapeutic concept was also shown in a clinically relevant large-animal model of myocardial infarction. - C. Michael Gibson, MD, said stents have transformed artery reopening, but patients still need a treatment that ensures capillaries open too. - Kevin Bainey, MD, said the goal is to save functioning heart muscle and that the drug could reduce heart failure, repeat hospitalizations and improve recovery after a heart attack.

Between the lines: - The study shifts attention from fixing the blocked artery to fixing the microvascular damage that can still limit recovery after reperfusion. - A capillary-selective approach could matter because it aims to restore flow without broadly disrupting normal blood pressure control. - The fact that the same biology may apply to acute kidney injury, ischemic stroke and organ transplantation hints at a broader platform beyond cardiology.

What's next: - PeriFlow Therapeutics is moving toward clinical trials with CLN-2501. - CLN-2501 remains the company’s lead development program as PeriFlow builds a portfolio of selective myosin inhibitors for pathological hypercontraction across tissue types. - If clinical results hold, the approach could add a new treatment layer after stenting for acute myocardial infarction. - More information: PeriFlow Therapeutics - More information: PeriFlow on LinkedIn

The bottom line: - The Nature study positions CLN-2501 as a potential first-in-class drug aimed at one of the biggest unmet needs in heart attack care: restoring capillary blood flow after the artery has already been reopened.